We are live on ! Find out more
JB

Julian Baker Baker Bros. Advisors

AUM $20B
1-Year Est. Return 154.41%
 

Julian Baker is co-managing member of Baker Bros. Advisors, a firm renowned for deep specialization in biotechnology and life sciences. The firm is known for concentrated positions, long holding periods, and scientific diligence that goes well beyond typical generalist research. Baker Bros. filings are closely watched by healthcare investors for signals in clinical-stage and commercial biotech.

This Fund
S&P 500
This Quarter Est. Return
-6.35%
1 Year Est. Return
+154.41%
3 Year Est. Return
+448.58%
5 Year Est. Return
+670.61%
10 Year Est. Return
+4,743.65%
AUM
$11.4B
AUM Growth
-$782M
Cap. Flow
+$157M
Cap. Flow %
1.38%
Top 10 Hldgs %
87.68%
Holding
124
New
6
Increased
21
Reduced
9
Closed
4

Top Buys

Rank Stock Value
1
ALXN
Alexion Pharmaceuticals
ALXN
+$234M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$100M
3
ASND icon
Ascendis Pharma A/S
ASND
+$10.6M
4
AVXS
AveXis, Inc. Common Stock
AVXS
+$9.37M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$6.88M

Top Sells

Rank Stock Value
1
ACOR
Acorda Therapeutics
ACOR
+$69.3M
2
DERM
Dermira, Inc.
DERM
+$14.2M
3
NBIX icon
Neurocrine Biosciences
NBIX
+$13.5M
4
EXEL icon
Exelixis
EXEL
+$11M
5
CERS icon
Cerus
CERS
+$9M

Sector Composition

Rank Sector Weight
1 Healthcare 99.03%
2 Technology 0%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CBAY
51
DELISTED
Cymabay Therapeutics
CBAY
$7.44M 0.07%
1,291,775
-121,724
-9% -$518K
RIGL icon
52
Rigel Pharmaceuticals
RIGL
$857M
$6.88M 0.06%
251,888
– –
INSM icon
53
Insmed
INSM
$27.5B
$6.86M 0.06%
400,000
– –
AGIO icon
54
Agios Pharmaceuticals
AGIO
$1.98B
$6.62M 0.06%
128,666
– –
MGNX icon
55
MacroGenics
MGNX
$261M
$6.37M 0.06%
363,676
– –
CBIO
56
Crescent Biopharma
CBIO
$637M
$6.29M 0.06%
5,633
+1,821
+48% +$1.5M
CFRX
57
DELISTED
ContraFect Corporation
CFRX
$5.87M 0.05%
5,057
– –
STML
58
DELISTED
Stemline Therapeutics, Inc.
STML
$5.83M 0.05%
633,497
– –
RNAC icon
59
Cartesian Therapeutics
RNAC
$304M
$5.76M 0.05%
9,660
+3,803
+65% +$1.68M
ASMB icon
60
Assembly Biosciences
ASMB
$700M
$5.16M 0.05%
20,833
– –
FSTX
61
DELISTED
F-star Therapeutics, Inc. Common Stock
FSTX
$5.05M 0.04%
93,286
+38,461
+70% +$1.78M
SYRE icon
62
Spyre Therapeutics
SYRE
$9.39B
$4.38M 0.04%
45,515
+37,916
+499% +$5.24M
ALBO
63
DELISTED
Albireo Pharma Inc
ALBO
$4.12M 0.04%
+200,000
New +$4.1M
LUMO
64
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$3.67M 0.03%
+55,556
New +$6.88M
NBRV
65
DELISTED
Nabriva Therapeutics plc Ordinary Shares Ireland
NBRV
$3.67M 0.03%
1,400
– –
EPZM
66
DELISTED
Epizyme, Inc
EPZM
$3.51M 0.03%
232,481
– –
OVID icon
67
Ovid Therapeutics
OVID
$547M
$3.5M 0.03%
+333,333
New +$4.35M
RARX
68
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$3.33M 0.03%
177,952
– –
ADMS
69
DELISTED
Adamas Pharmaceuticals
ADMS
$3.02M 0.03%
172,630
– –
ANAB icon
70
AnaptysBio
ANAB
$1.71B
$2.81M 0.02%
117,211
-32,789
-22% -$824K
ZGNX
71
DELISTED
Zogenix, Inc.
ZGNX
$2.69M 0.02%
185,290
-196,649
-51% -$2.47M
ALDR
72
DELISTED
Alder Biopharmaceuticals
ALDR
$2.49M 0.02%
217,328
– –
NTRA icon
73
Natera
NTRA
$47.9B
$2.48M 0.02%
228,676
– –
NVAX icon
74
Novavax
NVAX
$1.47B
$2.3M 0.02%
+100,000
New +$1.96M
AKTX
75
Akari Therapeutics
AKTX
$15.3M
$2.29M 0.02%
621
– –
1 2
3
4 5

Similar funds

ASRS
Arizona State Retirement System Phoenix, Arizona $19.9B AUM 44.71% 1-Year Est. Return
FWIA
Fort Washington Investment Advisors Cincinnati, Ohio $19.9B AUM 22.19% 1-Year Est. Return
CWP
Capital Wealth Planning Naples, Florida $20B AUM 25.34% 1-Year Est. Return
SFA
Sequoia Financial Advisors Akron, Ohio $20.1B AUM 24.77% 1-Year Est. Return
MGP
M&G plc London, United Kingdom $20.1B AUM 16.62% 1-Year Est. Return
JAM
Jupiter Asset Management London, United Kingdom $20.2B AUM 29.18% 1-Year Est. Return
Verition Fund Management
Verition Fund Management Greenwich, Connecticut $19.7B AUM 39.39% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $20.2B AUM 17.52% 1-Year Est. Return

Julian Baker's Q2 2017 Portfolio in Review

As of Q2 2017, Julian Baker held 124 positions worth $11.4B, down 6.4% from $12.2B the previous quarter. Its ten largest holdings account for 88% of the portfolio.

Julian Baker's Q2 2017 filing shows 6 new, 21 increased, 9 reduced and 4 closed positions. Its largest new stake was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M. The largest sale was Acorda Therapeutics, an estimated $69.3M.

By sector, the portfolio is most concentrated in Healthcare at 99% of assets, up from 98% a quarter earlier, followed by Technology.

  • Julian Baker's largest Q2 2017 buy was Lumos Pharma, Inc. Common Stock: 55,556 shares worth $3.67M.
  • Julian Baker added most to Alexion Pharmaceuticals in Q2 2017, an estimated $234M increase.
  • Julian Baker's biggest Q2 2017 reduction was Neurocrine Biosciences, cutting an estimated $13.5M.
  • Julian Baker fully exited Acorda Therapeutics in Q2 2017, selling an estimated $69.3M.
  • Julian Baker's ten largest holdings make up 88% of its $11.4B portfolio in Q2 2017.
  • Julian Baker opened 6 new positions and closed 4 in Q2 2017.
  • Julian Baker's portfolio value fell 6.4% quarter-over-quarter to $11.4B.

Based on Baker Bros. Advisors's 13F filing for Q2 2017, filed 14 Aug 2017.